Literature DB >> 7840185

Effect of prednisone on protein metabolism in Duchenne dystrophy.

Z Rifai1, S Welle, R T Moxley, M Lorenson, R C Griggs.   

Abstract

Prednisone improves strength in Duchenne dystrophy and changes the natural history of the disease. We studied the in vivo effects of prednisone (0.75 mg.kg-1.day-1) on muscle and whole body protein metabolism in six patients with Duchenne dystrophy and three patients with Becker dystrophy. Patients were admitted to the Clinical Research Center for study and consumed a constant flesh-free diet. Strength was measured by manual and quantitative muscle testing. Fractional muscle protein breakdown was estimated by the ratio of 3-methylhistidine to creatinine excretion determined in three consecutive 24-h urine collections. Whole body protein kinetics were studied in the postabsorptive state using a primed continuous infusion of L-[1-13C]leucine. Fractional muscle protein synthesis was determined from tracer incorporation into noncollagen muscle protein obtained by needle biopsy. After 6-8 wk of prednisone treatment, average muscle strength increased by 15% (P < 0.04), and 24-h creatinine excretion (an index of muscle mass) increased by 21% (P = 0.002). 3-Methylhistidine excretion decreased by 10%, but the change was not statistically significant. The ratio of 3-methylhistidine to creatinine excretion decreased by 26% (P < 0.04). Fractional muscle protein synthesis and whole body protein synthesis and breakdown did not change significantly. We conclude that the beneficial effect of prednisone on strength in Duchenne dystrophy appears to be associated with an increase in muscle mass, which may be mediated by inhibition of muscle proteolysis rather than stimulation of muscle protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840185     DOI: 10.1152/ajpendo.1995.268.1.E67

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  18 in total

1.  Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

Authors:  Ida Luisa Rotundo; Stefania Faraso; Elvira De Leonibus; Gerardo Nigro; Carmen Vitiello; Alessio Lancioni; Daniele Di Napoli; Sigismondo Castaldo; Vincenzo Russo; Fabio Russo; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

2.  New treatments for neuromuscular disease: optimism and obstacles.

Authors:  Hanns Lochmüller; Robert C Griggs
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 3.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

4.  Hydroxyl radical formation in skeletal muscle of rats with glucocorticoid-induced myopathy.

Authors:  Shingo Konno
Journal:  Neurochem Res       Date:  2005-05       Impact factor: 3.996

Review 5.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 6.  Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.

Authors:  Corrado Angelini; Enrico Peterle
Journal:  Acta Myol       Date:  2012-05

7.  Corticosteroid effects on ventilator-induced diaphragm dysfunction in anesthetized rats depend on the dose administered.

Authors:  Karen Maes; Anouk Agten; Ashley Smuder; Scott K Powers; Marc Decramer; Ghislaine Gayan-Ramirez
Journal:  Respir Res       Date:  2010-12-14

8.  Pregnancy-induced amelioration of muscular dystrophy phenotype in mdx mice via muscle membrane stabilization effect of glucocorticoid.

Authors:  Yuko Shimizu-Motohashi; Yoko Asakura; Norio Motohashi; Nandkishore R Belur; Michael G Baumrucker; Atsushi Asakura
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

9.  IRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cells.

Authors:  Pedro Miura; Meghan Andrews; Martin Holcik; Bernard J Jasmin
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

10.  Dystropathology increases energy expenditure and protein turnover in the mdx mouse model of duchenne muscular dystrophy.

Authors:  Hannah G Radley-Crabb; Juan C Marini; Horacio A Sosa; Liliana I Castillo; Miranda D Grounds; Marta L Fiorotto
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.